Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

1.6K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.6K
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

8.2K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Chromatin Immunoprecipitation- ChIP02:36

Chromatin Immunoprecipitation- ChIP

11.1K
Chromatin immunoprecipitation, or ChIP, is an antibody-based technique used to identify sites on DNA that bind to transcription factors of interest or histone proteins. It also helps determine the type of histone modifications such as acetylation, phosphorylation, or methylation.
Types of ChIP
ChIP can be divided into two types - X-ChIP and N-ChIP. X-ChIP involves in vivo cross-linking of histones and regulatory proteins to DNA, fragmenting the DNA by sonication, and isolating the protein-DNA...
11.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KATs in the MYST: A New Therapeutic Vulnerability for SETBP1-Mutated Myeloid Malignancies.

Blood cancer discovery·2026
Same author

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.

Leukemia·2026
Same author

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.

JMIR cancer·2026
Same author

Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation.

Science (New York, N.Y.)·2026
Same author

Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia.

Science advances·2025
Same author

Role of Chromatin Looping Factors in Leukemia.

Annual review of pathology·2025

Related Experiment Video

Updated: Jun 6, 2025

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.5K

Targeting chromatin modifying complexes in acute myeloid leukemia.

Alexandra Schurer1,2, Shira G Glushakow-Smith1,2, Kira Gritsman1,2,3,4,5

  • 1Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, United States.

Stem Cells Translational Medicine
|November 28, 2024
PubMed
Summary

Chromatin modification dysregulation drives acute myeloid leukemia (AML) relapse. Targeting menin-KMT2A and polycomb repressive complexes (PRC1/2) shows promise for AML treatment and overcoming resistance.

Keywords:
HOXA/BMEIS1KMT2AKMT2A-rearrangementNPM1cPRC1PRC2acute myeloid leukemiachromatinhistonesmenin inhibition

More Related Videos

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 6, 2025

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.5K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.1K

Area of Science:

  • Hematologic Oncology
  • Epigenetics
  • Chromatin Biology

Background:

  • Acute myeloid leukemia (AML) is characterized by high relapse rates, often linked to epigenetic dysregulation.
  • Aberrant histone modifications promote self-renewal gene expression in hematopoietic progenitors, driving leukemogenesis, particularly in MLL-rearranged (MLL-r) and NPM1-mutated AML.
  • Menin-KMT2A and polycomb repressive complexes (PRC1/2) are key regulators of these histone modifications and are implicated in AML progression.

Purpose of the Study:

  • To review recent findings on how leukemic cells exploit chromatin regulatory complexes for disease progression.
  • To discuss the therapeutic potential of targeting menin-KMT2A and PRC1/2 complexes in AML.
  • To explore novel combination therapies to address resistance to current monotherapies.

Main Methods:

  • Literature review of recent discoveries in AML epigenetics and chromatin regulation.
  • Analysis of preclinical and clinical studies on inhibitors targeting menin-KMT2A and PRC1/2 complexes.
  • Exploration of therapeutic strategies targeting broader interacting networks of these complexes.

Main Results:

  • Leukemic cells hijack menin-KMT2A and PRC1/2 complexes, along with other chromatin regulators, to promote AML.
  • Inhibitors targeting these complexes have shown therapeutic efficacy in preclinical and clinical settings.
  • Understanding these interactions is crucial for developing effective AML treatments.

Conclusions:

  • Targeting menin-KMT2A and PRC1/2 complexes represents a promising therapeutic avenue for AML.
  • Novel combination therapies targeting the broader interacting networks of KMT2A and PRC1/2 are needed to overcome treatment resistance.
  • Further research into epigenetic mechanisms driving AML is essential for improving patient outcomes.